Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
22 févr. 2024 16h05 HE
|
Relay Therapeutics, Inc.
Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
Relay Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights on February 22, 2024
15 févr. 2024 16h05 HE
|
Relay Therapeutics, Inc.
Relay Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights on February 22, 2024
Relay Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
01 févr. 2024 16h05 HE
|
Relay Therapeutics, Inc.
Relay Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Relay Therapeutics Announces $30 Million Private Placement Financing
08 janv. 2024 07h00 HE
|
Relay Therapeutics, Inc.
Relay Therapeutics Announces $30 Million Private Placement Financing
Relay Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
02 janv. 2024 16h05 HE
|
Relay Therapeutics, Inc.
Relay Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
Relay Therapeutics to Participate in Stifel 2023 Healthcare Conference
07 nov. 2023 16h05 HE
|
Relay Therapeutics, Inc.
Relay Therapeutics to Participate in Stifel 2023 Healthcare Conference
Relay Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Highlights
02 nov. 2023 16h05 HE
|
Relay Therapeutics, Inc.
Relay Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Highlights
Relay Therapeutics to Announce Third Quarter 2023 Financial Results and Corporate Highlights on November 2, 2023
26 oct. 2023 16h05 HE
|
Relay Therapeutics, Inc.
Relay Therapeutics to Announce Third Quarter 2023 Financial Results and Corporate Highlights on November 2, 2023
Relay Therapeutics Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors
12 oct. 2023 16h05 HE
|
Relay Therapeutics, Inc.
Relay Therapeutics Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors
Relay Therapeutics to Present Clinical Data on RLY-4008 in Advanced FGFR2-Altered Solid Tumors at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
18 sept. 2023 16h05 HE
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...